Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. is advancing its plant-based recombinant human serum albumin industrialization base project, which is expected to significantly impact domestic supply and health security by reducing reliance on imported products [3][5]. Group 1: Project Development - The construction of the first phase of the industrialization base is underway, with 490 workers on-site as of June 3 [1]. - The main structure of the project was completed in late April, and internal construction is currently ongoing, with equipment installation and debugging scheduled for July [3]. - The project is expected to be operational by the second quarter of 2026, with a total building area of approximately 70,000 square meters [3]. Group 2: Production Capacity and Strategic Importance - Once completed, the facility is projected to produce 12 million doses of recombinant human serum albumin injection annually, which could replace about 25% of the domestic import volume [3][5]. - The project is deemed strategically significant for public health and national defense, as it aims to ensure a stable supply of essential medical products [3][5]. Group 3: Innovation and Technology - Heyuan Biotechnology has developed the world's first plant-based recombinant human serum albumin using rice, marking a significant innovation in the field [5][6]. - The company has established a unique plant expression system and four core technology platforms, which are crucial for the development of new drugs [6].